Revolution Medicines, Inc. (RVMD)
211.58
+2.12
(+1.01%)
USD |
NASDAQ |
Aug 24, 16:00
211.40
-0.18
(-0.09%)
After-Hours: 20:00
Revolution Medicines Enterprise Value : 42.13B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 42.13B |
| August 20, 2026 | 42.62B |
| August 19, 2026 | 43.24B |
| August 18, 2026 | 43.53B |
| August 17, 2026 | 42.67B |
| August 14, 2026 | 40.90B |
| August 13, 2026 | 40.53B |
| August 12, 2026 | 41.23B |
| August 11, 2026 | 41.29B |
| August 10, 2026 | 41.59B |
| August 07, 2026 | 41.20B |
| August 06, 2026 | 39.63B |
| August 05, 2026 | 39.52B |
| August 04, 2026 | 38.70B |
| August 03, 2026 | 36.34B |
| July 31, 2026 | 37.43B |
| July 30, 2026 | 38.42B |
| July 29, 2026 | 36.01B |
| July 28, 2026 | 36.64B |
| July 27, 2026 | 37.55B |
| July 24, 2026 | 37.79B |
| July 23, 2026 | 37.69B |
| July 22, 2026 | 36.47B |
| July 21, 2026 | 36.52B |
| July 20, 2026 | 35.90B |
| Date | Value |
|---|---|
| July 17, 2026 | 37.14B |
| July 16, 2026 | 35.64B |
| July 15, 2026 | 36.77B |
| July 14, 2026 | 36.88B |
| July 13, 2026 | 36.66B |
| July 10, 2026 | 37.29B |
| July 09, 2026 | 38.20B |
| July 08, 2026 | 37.91B |
| July 07, 2026 | 38.06B |
| July 06, 2026 | 37.96B |
| July 02, 2026 | 37.80B |
| July 01, 2026 | 37.43B |
| June 30, 2026 | 37.38B |
| June 29, 2026 | 37.09B |
| June 26, 2026 | 34.98B |
| June 25, 2026 | 34.20B |
| June 24, 2026 | 32.51B |
| June 23, 2026 | 32.46B |
| June 22, 2026 | 31.72B |
| June 18, 2026 | 31.16B |
| June 17, 2026 | 30.11B |
| June 16, 2026 | 29.87B |
| June 15, 2026 | 30.57B |
| June 12, 2026 | 29.33B |
| June 11, 2026 | 28.40B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tango Therapeutics, Inc. | 3.039B |
| Erasca, Inc. | 5.286B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Intellia Therapeutics, Inc. | 1.433B |
| Beam Therapeutics, Inc. | 2.168B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -644.37M |
| Total Expenses (Quarterly) | 644.37M |
| EPS Diluted (Quarterly) | -3.055 |
| Earnings Yield | -4.17% |
| Normalized Earnings Yield | -3.880 |